Castle Biosciences Inc (NAS:CSTL)
$ 24.37 0.63 (2.65%) Market Cap: 672.79 Mil Enterprise Value: 458.63 Mil PE Ratio: 0 PB Ratio: 1.67 GF Score: 79/100

Castle Biosciences Inc at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 04:00PM GMT
Release Date Price: $17.68 (-0.23%)
Kyle Mikson
Cannacord Genuity - Analyst

Welcome to the Canaccord Genuity global growth conference. I'm Kyle Mikson, over at life science, tools, and diagnostics for Canaccord. Pleased to have Castle Biosciences here with us today. Castle is a company that provides many diagnostic tests across dermatology, cancer, mental health, and GI cancer as well. So we have Derek Maetzold, the CEO of the company, and he's going to run through some slides to start us off. So go ahead, Derek, thanks for joining.

Derek Maetzold
Castle Biosciences, Inc. - President, CEO & Director

Thank you, Kyle and Canaccord, for the opportunity to be here in Boston yet again. Let's get started here. So let's see, disclaimer slide. So Castle Biosciences is a molecular diagnostics company predominantly focused on providing high-value diagnostic tests that help inform better patient management for a variety of conditions. Our largest franchise is in dermatology, where we have three proprietary gene expression profile tests: DecisionDX-Melanoma, DecisionDx-SCC, and MyPath Melanoma.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot